US FDA Approved Jemincare to Initiate Clinical Trial of Neutra...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SHANGHAI, Apr. 2, 2021 /Xinhua-AsiaNet/-- On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.Preclinical data...
Authors: LATEST ASIANET NEWS RELEASES